Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: PTCA v. CABG

This article was originally published in The Gray Sheet

Executive Summary

PTCA v. CABG: Investigators in the 1,829-patient, randomized BARI trial report "no significant difference" by treatment strategy in five-year survival, as well as survival free of myocardial infarction, between multivessel coronary artery disease patients treated with percutaneous transluminal coronary angioplasty and those treated with coronary artery bypass grafting. The study -- funded by the National Heart, Lung and Blood Institute -- also found a "trend of better survival" among bypass patients, but determined that the trend was accounted for by "excess mortality among treated diabetics assigned to an initial PTCA strategy." A cost analysis of the two procedures found that "average overall costs were 4% higher for a strategy of initial coronary artery bypass," leading to average savings of $2,000 with PTCA...

You may also be interested in...



AAM Criticizes Lower Health Care Costs Act

Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.

USCMA Revision Worsens Innovator Woes In Canada

Stripping the revised USMCA deal of provisions to strengthen IP rights for biologics will worsen market difficulties in Canada caused by changes to the drug pricing regime, says industry.

A Steady Year For The Top Tier In Pharma Ahead Of Major Upheaval

Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.

UsernamePublicRestriction

Register

MT005110

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel